Does the Use of a Genomic Tumor Board Increase the Number of Patients Who Receive Genome-Informed Treatment (NCT05455606)
A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy
🩺 Plain-English Summary (8th-Grade Level)
This clinical trial studies how well an educationally enhanced genomic tumor board (EGTB) intervention works to increase the number of patients with solid tumors that have come back (recurrent), do not respond to treatment (refractory), have spread to other parts of the body (metastatic), or are newly diagnosed and spread to other parts of the body (advanced) who receive genome-informed treatment. Genome-informed treatment refers to treatment based on the information found in genomic tumor test results. This study compares the usual approach to reviewing genomic tumor test results with the approach of having a genomic tumor board (GTB) review the test results. A GTB is team of doctors and scientists that have experience in understanding genomic changes and review genomic tumor test results. The tumor board helps to suggest whether there are other cancer treatment options based on patient genetic test results. The usual approach is to review genomic tumor test results without the GTB being involved. This study may help researchers learn if using a GTB enhances the treatment decision making process within 6 months of joining the study. This study may also help researchers learn if using the GTB increases doctors' understanding of genomic tumor test results and increases doctors' comfort level with genomic tumor tests.
Who can join: Review the eligibility criteria below.
Location: Cancer Center at Saint Joseph's — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
- Best Practice (OTHER)
- Chart Abstraction (OTHER)
- Educational Intervention (OTHER)
- Genomic Profile (PROCEDURE)
- Interview (OTHER)
- Questionnaire Administration (OTHER)
- Tumor Board Review (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (72 Sites)
Showing the first 25 of 72 sites.
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler — Savannah, Georgia
- Hawaii Cancer Care Inc - Waterfront Plaza — Honolulu, Hawaii
- Queen's Medical Center — Honolulu, Hawaii
- Straub Clinic and Hospital — Honolulu, Hawaii
- University of Hawaii Cancer Center — Honolulu, Hawaii
- Kapiolani Medical Center for Women and Children — Honolulu, Hawaii
- Hawaii Cancer Care - Westridge — ‘Aiea, Hawaii
- Pali Momi Medical Center — ‘Aiea, Hawaii
- Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
- Illinois CancerCare-Bloomington — Bloomington, Illinois
- Illinois CancerCare-Canton — Canton, Illinois
- Carle at The Riverfront — Danville, Illinois
- Illinois CancerCare-Galesburg — Galesburg, Illinois
- Carle Physician Group-Mattoon/Charleston — Mattoon, Illinois
- Illinois CancerCare-Ottawa Clinic — Ottawa, Illinois
- Illinois CancerCare-Peoria — Peoria, Illinois
- Carle Cancer Center — Urbana, Illinois
- Iowa Methodist Medical Center — Des Moines, Iowa
- Medical Oncology and Hematology Associates-Des Moines — Des Moines, Iowa
- HaysMed University of Kansas Health System — Hays, Kansas
- Lawrence Memorial Hospital — Lawrence, Kansas
- Olathe Health Cancer Center — Olathe, Kansas
- University of Kansas Cancer Center-Overland Park — Overland Park, Kansas
- Salina Regional Health Center — Salina, Kansas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Malignant Solid Neoplasm
- Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer — New Brunswick, New Jersey
- Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer — Houston, Texas
- Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic — Houston, Texas
- Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin — Duarte, California
- Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors — Houston, Texas
- Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study — Houston, Texas
Explore by condition: All Advanced Malignant Solid Neoplasm clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.